Avacta
Momentum builds in Diagnostics and TherapeuticsAvacta
Diagnostics build-out continues with Coris acquisitionAvacta
Building on Therapeutic and Diagnostic foundationsAvacta
FY22 results point to progress across Tx and DxAvacta
AVA6000 shows signs of successful tumour targettingAvacta
Diagnostics business back into the spotlightAvacta
Diagnostics M&A-led growth strategy is ready to LaunchAvacta
Building Tx and Dx portfolios from proprietary platformsAvacta
AVA6000 set for third dose escalation stageAvacta
FY21 results: a year of frustrations and opportunities